Andrey Skvortsov
0000-0003-2712-927X
30 papers found
Refreshing results…
Changes of NT-proBNP and sST2 levels for predicting isolated episodes of ventricular tachyarrhythmias and electrical storm in patients with systolic heart failure and various implanted devices
Possibilities of modern biomarkers for assessing the risk of developing ventricular tachyarrhythmias and sudden cardiac death in patients with chronic heart failure
Soluble ST2 – biomarker for prognosis and monitoring in decompensated heart failure
Multimarker Approach in Risk Stratification of Patients with Decompensated Heart Failure
Features of diagnostics and treatment of chronic heart failure in elderly and senile patients. Expert opinion of the Society of Experts in Heart Failure, Russian Association of Gerontologists, and Euroasian Association of Therapists
Clinical significance of serial biomarkers activity determination after acute heart failure decompensation: sST2 NT-proBNP role during long-term follow-up
Head to Head Comparison of Suppression of Tumorogenicity 2 and Copeptin Significance for Prognosis of Patients After Acute Heart Failure Decompensation
[Soluble Suppression of Tumorogenicity 2 Increases Opportunities for Risk Stratification After Acute Heart Failure Decompensation].
Therapy of High Risk Patients After Decompensation of Heart Failure Under NT-proBNP Control. Main Results
The Role of Markers of Organ Damage in Patients With Chronic Heart Failure
Treatment of patients with chronic heart failure based on monitoring of concentrations of natriuretic peptides - To what extent it is justified in clinical practice?
Prevalence and diagnosis of dilated cardiomyopathy. Results of the registry of dilated cardiomyopathy in the Russian Federation
[Does percutaneous myocardial revascularization affect the course and prognosis of chronic heart failure?].
[Epidemiology of dilation cardiomyopathy].
Galectin-3 - A new biomarker for diagnostics and outcome of chronic heart failure
[The use of polyunsaturated fatty acids in heart failure].
The role of hypotension as a factor of unfavorable prognosis in patients with chronic heart failure
[Inflammatory cardiomyopathy: state-of-the-art].
Is it always necessary to use triple combination in the treatment of patients with chronic cardiac failure? Choice of the third neurohormonal blocker
Effect of long term therapy with spironolactone on parameters of 24-hour heart rhythm variability and ventricular arrhythmias in patients with heart failure receiving optimal therapy
Missing publications? Search for publications with a matching author name.